# Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement

> **NCT06594432** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** R-CHOP+Z+MTX
- **DRUG:** R-CHOP+MTX

## Key facts

- **NCT ID:** NCT06594432
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594432, "Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06594432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*